Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMYX7VI)

Drug Name
Rintatolimod Drug Info
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Phase 3 [1]
Cross-matching ID
PubChem CID
135537060
TTD Drug ID
DMYX7VI

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 3 (TLR3) TTD24Y0 TLR3_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Toll-like receptor 3 (TLR3) DTT TLR3 4.256 5.833 5.916 6.583
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Human immunodeficiency virus infection
ICD Disease Classification 1C62
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 3 (TLR3) DTT TLR3 4.85E-01 0.63 0.83
Toll-like receptor 3 (TLR3) DTT TLR3 8.00E-01 0.11 0.1
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02151448) alphaDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies. U.S. National Institutes of Health.
2 A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334.